Azenta Valuation

Is BA3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BA3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BA3 (€50) is trading above our estimate of fair value (€21.02)

Significantly Below Fair Value: BA3 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BA3?

Other financial metrics that can be useful for relative valuation.

BA3 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.1x
Enterprise Value/EBITDA128.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BA3's PS Ratio compare to its peers?

The above table shows the PS ratio for BA3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.3x
GXI Gerresheimer
1.7x10.4%€3.5b
EVT Evotec
1.9x13.1%€1.5b
1SXP SCHOTT Pharma KGaA
4.6x11.7%€4.1b
SRT3 Sartorius
5.1x10.3%€15.2b
BA3 Azenta
4.5x7.0%€2.9b

Price-To-Sales vs Peers: BA3 is expensive based on its Price-To-Sales Ratio (4.5x) compared to the peer average (3.3x).


Price to Earnings Ratio vs Industry

How does BA3's PE Ratio compare vs other companies in the European Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.7%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.7%
n/an/an/a
No more companies

Price-To-Sales vs Industry: BA3 is good value based on its Price-To-Sales Ratio (4.5x) compared to the European Life Sciences industry average (4.7x).


Price to Sales Ratio vs Fair Ratio

What is BA3's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BA3 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.5x
Fair PS Ratio3x

Price-To-Sales vs Fair Ratio: BA3 is expensive based on its Price-To-Sales Ratio (4.5x) compared to the estimated Fair Price-To-Sales Ratio (3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BA3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€50.00
€58.06
+16.1%
15.9%€73.26€48.22n/a5
Jun ’25€46.80
€58.06
+24.0%
15.9%€73.26€48.22n/a5
May ’25€49.40
€62.71
+26.9%
13.2%€74.17€52.57n/a5
Apr ’25€55.50
€66.74
+20.3%
7.8%€73.23€59.33n/a4
Mar ’25€60.00
€66.44
+10.7%
7.8%€72.90€59.06n/a4
Feb ’25€60.00
€66.24
+10.4%
8.5%€72.68€57.96n/a4
Jan ’25€59.50
€53.46
-10.2%
11.5%€62.14€45.69n/a4
Dec ’24€51.50
€53.46
+3.8%
11.5%€62.14€45.69n/a4
Nov ’24€42.20
€55.63
+31.8%
11.5%€64.67€47.55n/a4
Oct ’24€47.40
€55.83
+17.8%
7.2%€61.50€52.04n/a4
Sep ’24€52.00
€53.75
+3.4%
7.2%€59.22€50.11n/a4
Aug ’24€42.40
€47.58
+12.2%
17.3%€60.48€40.02n/a4
Jul ’24€42.60
€48.74
+14.4%
19.4%€63.13€38.99n/a4
Jun ’24€40.20
€48.74
+21.2%
19.4%€63.13€38.99€46.804
May ’24€39.20
€54.98
+40.3%
18.0%€64.15€40.32€49.405
Apr ’24€40.01
€60.49
+51.2%
7.9%€65.55€53.37€55.505
Mar ’24€41.34
€60.49
+46.3%
7.9%€65.55€53.37€60.005
Feb ’24€51.88
€66.70
+28.6%
9.0%€73.90€58.74€60.005
Jan ’24€54.06
€67.53
+24.9%
9.9%€75.25€57.88€59.505
Dec ’23€58.58
€67.53
+15.3%
9.9%€75.25€57.88€51.505
Nov ’23€44.39
€69.08
+55.6%
10.3%€77.99€60.77€42.205
Oct ’23€44.88
€75.35
+67.9%
10.7%€89.94€67.95€47.405
Sep ’23€51.93
€80.64
+55.3%
17.9%€108.52€67.70€52.006
Aug ’23€66.12
€90.72
+37.2%
14.6%€118.88€80.57€42.406
Jul ’23€67.89
€90.53
+33.3%
11.8%€112.93€79.33€42.606
Jun ’23€70.85
€91.99
+29.8%
11.8%€114.74€80.61€40.206

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.